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ABSTRACT
Dosimetry of internal emitters is entirely a post-war development. From the first definitive
paper on the subject appeared in 1948 to the present day MIRD schema, there has been a
continued advance in ‘our  knowledge of radionuclide decay data, radiation interaction
cross-sections, computational methods for obtaining absorbed fractions, mathematical
description of anthropometric models, collection and analysis of biokinetic data of internal
emitters.
After listing out the developments in radiation  dose units, the present review briefly
summarises the physical and biological bases of the estimation of the mean organ radiation
dose, specifically mentioning the contributions from the Institute of Nuclear Medicine and
Allied Sciences. The shortcomings of the conventional ‘mean organ dose’ concept have been
brought out, highlighting recent developments in local dosimetry and microdosimetry. The
expected potential future developments in dosimetry of internal emitters are also enumerated.
1. INTRODUCTION
Dosimetry of internal emitters is a mature branch of radiological science with a
rich heritage, a well-established present, and holding out bright prospects for the
future. The first paper on this subject based on the concepts of specific gamma ray
constant and geometric factor was published in 1948 (Quimby’). The present review
lists out the salient developments in dosimetry prior to the era of absorbed fractions
and briefly brings out the significant contributions made by scientists from INMAS
(Institute of Nuclear Medicine and Allied Sciences) in applying absorbed fractions
Received 24 September 1990
389
390 A R Reddy, et al
for practical dosimetry in various nuclear medicine procedures and in computing
HILED  (highly localised energy density) dosimetry. It also enumerates the areas in
which the future of internal dosimetry lies, particularly in finding the radiobiological
significance of microdosimetry.
2. DEVELOPMENTS IN PRE-ABSORBED FRACTION ERA
2.1 Units of Radiation Dose
1906: Eve suggested an indirect approach to the measurement of the energy absorbed
in a tissue medium, namely, the determination of the number of ion pairs produced
during the absorption of the radiation and the energy absorbed per ion pais.  Hence
it is important to note that Eve has anticipated the basic ideas of both the units
roentgen and rad which were introduced much later.
1911: Mme Curie prepared a standard of a carefully weighed and analysed sample of
a radium salt3. Specifications were made in terms of milligrams of radium element.
1919: Regaud, a leading French doctor who was using radium for therapy, called
attention to the differences between emitted, delivered, and absorbed doses, but
admitted that the only unit that could be used at that time was milligram-hours3.
2.2 Biological Units of Dose
1918: Russ proposed the first biological unit  of radiation4. Defined as the amount of
radiation necessary to kill mouse cancer cells, this experimental quantity w&  called
rad.
1919: Ghilarducci suggested the amount of radiation required to produce ulceration
in the intestines of ratr?.  Another alternative was the killing dose for small biological
organisms such as Ascaris or Drosophila eggs. Perhaps the most practical parameter
was the amount to produce erythema on the human skin.
None of the above biological experiments or suggestions could be standardised
in view of the wide variability and strong dependence on various physical factors.
Hence it was realised that a chemical or physical reaction would be preferable to a
biological one.
2.3 Physical  Units of Radiation Dose
1913: Rutherford and Robinson made the first attempts to measure heat resulting
from absorption of radioactive radiations in a small region6.  But the attempts were
not successful.
1920s: A unit, roentgen, had been developed for x-rays in the 100 to 200 keV region,
which offered a beginning for dose standardisation with x-radiations. Gamma radiation
from a point source of radium had also been measured in terms of roentgen. To be
more specific, the value ranged from 8.4 to 8.6 R per milligram-hour from a point
source of radium at a distance of 1 cm. The unit roentgen was officially adopted by
the International Congress of Radiology in 1928.
1922: Quimby prepared tables of data of the dose delivered for about 200 applicator
sizes and distances7.
1947: Meredith calculated tables of data in terms of number of milligram-hours
necessary to deliver 1000 R at the point in question’.
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1948: Paterson and Parker calculated a value of 8.4 R per milligram-hour for a point
source of radium at 1 cm distanceg.  This is called the dose delivered.
2.4 Radiation Dose From Radioactive Substances
1941: Marinelli published the first approach to the problem of radiation’dosage from
a radioactive material”, viz., 32P.  He invented a new unit, which he called the
equivalent roentgen, resulting from total decay of a particular amount of radionuclide
in one gram of air which would result in the same number of ion pairs as would be
produced when it is exposed to 1 R of x-rays. In order to obtain the dose to a patient
or a particular tissue, it is oecessary  to determine the number of beta particles released
per unit volume (or unit mass) of tissue.
1948:  Marinelli, et al published the method of dosage calculation for other
radionuclides, wherein they introduced the concept of ‘effective half-life’ to take into
account the influence of physiological excretion of the nuclide in addition to its physical
radioactive decay”. Dose was still expressed in terms of roentgens and it was called
as dose delivered (in present day understanding exposure). The same authors
introduced a new parameter called ‘specific gamma constant’ for gamma dosimetry.
It was expressed as the exposure in roentgens at 1 cm distance from a uniform point
source of 1 mCi in air during 1 hour and was calculated for a number of radionuclides.
Early  1950s: A new unit, called the rad, which is equal to 100 ergs absorbed per
gram of the absorbing material, was invented to express the parameter dose absorbed.
Thus if the radionuclide concentration in the target of interest is known, absorbed
dose, from either beta particles or gamma photons or from both, could be calculated
from the above information.
1964: ‘Absorbed fraction’ was defined by Ellett, Callahan and Brownelln.  Its values
for a number of geometries of different sixes and for different photon energies
computed by Monte Carlo method have been published. L
1968: A new era of internal dose for biologically distributed radionuclides began
with the acceptance of the schema proposed by Loevinger and Berman13  to MIRD
(Medical Internal Radiation Dose) Committee of the American Society of Nuclear
Medicine, and with the publication of MIRD schema as well as data on dose build-up
factors (Berger”)  and data on. absorbed fractions by Brownell, -et # as MIRD
pamphlets. Subsequently, data on radionuclide decay schemas,  ‘reference man’,
‘specific absorbed fractions’ as well as S-factors for a large number of source and
target organs of the reference man have been published as MIRD pamphlets. The
MIRD schema has provided a unified approach for dose estimate for any type of
radiation and target well as source organ, thus scoring a ,great  advantage over the
Marine&Quimby-Hine  formalism of 1948.
2.5 Physical Basis of Internal Dosimetry
The Marinelli-Quimby-Hine system” of internal radiation dose calculation was
based on distinguishing the radiation as penetrating and non-penetrating. Gamma
photons are examples of penetrating radiation and electrons are non-penetrating
radiation. For non-penetrating radiations, all the energy is assumed to be absorbed
in the target, unless the target of interest is much smaller than the range of electrons
emitted. Calculations of 13r1 dosimetry in small spheres have taken into consideration
the partial absorption of beta radiations W’ For photons, two parameters, viz.,.
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‘gamma ray exposure rate constant’ (Z”)  and ‘average geometric factor’ (g)  are
considered. The former encompasses (roughly) radionuclide decay characteristics as
well as the photon energy absorption coefficient in air or tissue of interest and is
expressed in R/mCi-hr at 1 cm from a point source. The parameter average geometric
factor, 8, is to take care of shape of the target in which the source is uniformly
distributed. Here it is assumed that the photons (both primary and secondary) can
be represented by an ‘effective absorption coefficient’, peff  equal to either zero (when
the target has linear dimensions less than 10 cm), or 0.028 cm-’ when it is larger.
These assumptions are valid when the emitted photon energy is greater than a few
hundred keV.  Focht, et al calculated the values of 9’ for spheres and cylinders of
different sizes l8 Tables of gamma.
radionuclides; are also available”.
ray exposure constants for commonly used
3. ABSORBED FRACTION ERA
Absorbed fraction system of Marinelli, et all’ has been extensively used for
dosimetry of internal emitters until recently. However, with the increasing use of low
energy photon emitters (for example, ‘x’“‘Tc)  for nuclear medicine procedures,
questions have been asked about the validity of the assumption of an effective
absorption coefficient of either 0 or 0.028 cm-‘, whatever the target size or photon
energy is. The argument is valid in view of the rapid variation of the linear absorption
coefficient with photon energies less than 100 keV.  Satisfactory solutions to these
arguments have become possible with the availability of detailed photon interaction
data compilations at the National Bureau of Standards, USA, and advanced
semi-analytical computational techniques on large computers. The pioneering papers
of Ellett, Callahan, Brownell and Reddy first introduced the concept of ‘photon
absorbed fraction’ and its computation using Monte Carlo techniques for regular
geometries (such as elliptic cylinders, ellipsoids, spheres, straight cylinders, etc) of
different sizes having either point or uniform source distributions emitting photons
of energies from 20 keV to 2 MeV’2*20. Using more sophisticated sampling techniques
Snyder, et al at Oak Ridge National Laboratory obtained absorbed fractions for a
homogeneous tissue equivalent mathematically defined anthropometric phantom2’..
To establish a uniform method of radiopharmaceutical dosimetry, the Society of
Nuclear Medicine of USA formed MIRD Committee which brought out its first
pamphlets in 1968 r3 lJ In MIRD Pamphlet 1, Loevinger and Berman13  formulated a- .
schema for internal dose estimation based on the concepts of ‘absorbed fraction’ and
‘specific absorbed fraction’. Minor revisions to the above were brought by the same
authors in 1976.
The schema may be outlined as follows: Radioactive materials administered to
a patient are distributed in the various body regions, r,, r,, . . ..r..  Regions can be
points, lines, surfaces or volumes. Certain portions of the body may be considered
as ‘target’ volumes, these being designated by v. The average absorbed dose in v from
r, is-equal to the energy absorbed in v which originates in r, and is symbolised
by D (v+r,,), given by:
3 (vwj,) = A7, (tl,  t2)  C Ai pi (v+q,)
= 47, S (v4-rh),my
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where A,, ( tl, 4) is the cumulated activity in &i hr given by $&(t)dt;  Ai is the
equilibrium dose constant or mean energy emitted per unit cumulated activity in
g rad/&i hr; Gi (v+J is the fraction of radiation energy of type i released in source
region h, and absorbed in target v, m, is the mass of the target v in g;‘A,, is the activity
administered to the patient, r,,  is the residence time, and A,,r,, = A,, (tr,  4); S(vtr,)
is the mean absorbed dose per unit cumulated activity in rad per&i hr.
MIRD Committee systematically collected and published data that pertain to
different parameters of the above dose equation. Radionuclide decay data for
computation of Ai for more than 100 radionuclides have appearedZ  as MIRD Pamphlet
10. Photon absorbed fraction data for regular geometries of different sizes,
homogeneous tissue equivalent medium, and uniform source distribution have been
the subject matter of MIRD PimpliIets  3 and 181sp23. Values of S-factors for a
heterogeneous anthropometric adult reference man phantom for different s’ource
locations were listed-in MIRD Pamphlet 11 for 117 radionuclides21.  Electron absorbed
fraction data for monoenergetic point electron sources or beta emitters were tabulated”
in MIRD Pamphlet 7.
To facilitate calculation of radiation doses to different age groups, mathematical
phantoms have been developed for the age groups of 0 (new-born), 1,5,  10 and 15
years. S-factors have been computed ‘for a number of targets containing radioactivity
in different age groups. A variety of computer software systems have been developed
for the users of time-sharing or minicomputers for computing internal radiation doses,
Parallel to these developments of unified MIRD schema based on the concept
of absorbed fraction, simpler methods of refining the parameters of Marinelli, et al
dose equation have been evolved. One such refinement developed at INMAS was to
intioduce the ‘modified geometric factor’ approachB.  In this method, using the linear
attenuation coefficients ,of  each photon energy and dose build-up factors for each of
the source-to-target distances, the. limitation of the earlier effective absorption
coefficient is minimised. Tables of average geometric factors and absorbed fractions
derived therefrom have been published for spheroids of a variety of sizes and
eccentricities. Reddy and Mehta have extended the lower limit of the photon energy
to 1 keV and spherical target sizes of micron dimension8’.
At this point it must be emphasised that all the physical data tabulated so far,
either based on geometric factors or absorbed fractions, are for specific mathematically
defined models. Therefore the dose estimates at best to these models are to be used
only as guidelines for humans.
3.1 B&do&al  Basis of lntemal  Dosimetry
The parameter tha&comprises  the biokinetic behaviour of the internal emitter is
the cumulated activity Ah (tl,  t2) expressed in &i-hr. The same parameter was split
into three, viz., activity administered, fractional uptake, and effective mean life
(1.44 times the effec$ve  half-life) in the Marinelli-Quimby-Hine dose formalism. The
cumulated activity Ah in a region r, can be described mathematically, based on a
measured set of data points at different times. For- a number of internal emitters,
ICRP published the biological data required for calculating A”,  based on
multi-exponential and power function fits. Kaul, et al have compiled the available
biokinetic data for several radiopharmaceuticals”. MIRD Committee also collected
biokinetic data for different radiopharmaceuticals and analysed them by sophisticated
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simulation techniques to get the cumulated activities. The Committee has brought
out summary dose estimate reports for several radiopharmaceuticals28.
However, appreciable alterations in the data are produced in case of pathology
intrinsic to the organ of interest. For example, with 13’ERose  Bengal, the estimated
Tefi  in normal and hepatitis cases are respectively 0.062 and 2.2 d; the consequent
absorbed doses (rad/mCi) are 12 and 440 respectively. In case of intrahepatic disease,
the per cent administered activity in urine was 30 as against 25 per cent in normals.
Hence the consequent absorbed doses are 4.67 and < 0.78 rad per mCi respectively.
Such appreciable alterations in metabolism are also observed in patients undergoing
radiotherapy and chemotherapf9.
At this stage it might be concluded that there exists a sound physical base for
accurate internal average dose estimates to model organs under the MIRD schema.
. Although sophisticated computational methodologies for analysing biokinetic data of
radiopharmaceuticals exist, the basic availability of data itself is scanty, more so for
humans.
3.2 Efforts at INMAS
During this period significant contributions to dosimetry of internal emitters were
made by scientists from INMAS with active encouragement from the late Brig.
Mazumdar. Sastry, et al estimated radiation doses from (i) a chelating agent like
DTPA labelled  with 113m1n, “‘In,  and iasYh used for kidney function and brain
scanning, (ii) 113m1n iron hydroxide macroaggregates used for lung scanning in different
age groups, and (iii) 113ml~ colloid used for liver scanning in different age group#‘.
Sastry, et al have estimated radiation doses from 13’I-HSA,  ‘=fiHSA,  %Tc-HSA
and 113ml~ chloride used for placental investigations to ascertain the relative merits
of the different radiopharmaceuticals 31 They have also estimated radiation doses to.
different organs of both mother and fetus. Reddy in collaboration with Elasser, et al
has computed specific absorbed fractions and S-factors for calculating absorbed dose
to embryo/fetus and has presented the dosimetry of fetal tissues for 1311  and 59Fe  using
biokinetic data for various stages of pregnancy32 Reddy and Mehta have recently.
reviewed33  the information available for estimating embryo/fetus dosimetry in
situations where the radioactivity was inadvertently administered to pregnant women
(who were not aware at that time that they were pregnant) and presented as an
example a case study of 1311 administered to a patient of thyroid cancer in such a
situation.
As early as 1971, Sastry, et al reviewed radiation .doses in paediatric  radioisotopic
investigations and presented absorbed fractions as a function of age for various energies
along with a summary of the radiation doses for different age groups received by the
whole body and specific organs for some commonly used diagnostic tests”.
4. POST-ABSORBED FRACTION ERA
The concept of mean organ dose and the method of calculating it by MIRD
schema are valid only if it is assumed that the activity is uniformly distributed
throughout the source region. When viewed macroscopically, the assumption is valid
for most of the nuclear medicine investigations and hence the mean organ dose is
taken as an index of the potential hazard due to the radioisotopic investigation.
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However, with the availability of sophisticated experimental methods of
determination of microscopic localisation  and biokinetics of the administered activity
combined with complex mathematical models of the organ and a variety of computer
methodologies, the dosimetry can be made at any level to a target of interest. But at
what level should the dosimetry be done? Is the conventional calculation of absorbed
dose at the organ level, assuming a uniform concentration of radionuclide, not
sufficient? Or should we go down to the assumed models of tissue, cellular and even
subcellular structures? Reddy, et al examined the problem in detail taking 131Z  vs **‘I
in thyroid, 203Hg vs lwHg neohydrin in kidney, and thorotrast (“Th) in liver as
examples35. Significant differences between the mean organ dose and dose to a relevant
microstructure (such as apical membrane in the cells of thyroid follicles in case of
thyroid, epithelial cells lining the proximal tubules of the cortex in the case of the
kidney, and nuclei of cellular structures in reticuloendothelial system of liver) were
found.
Reddy and Kaul have computed detailed microscopic dose distributions across
thyroid follicles of varying sixes for a number of radioiodine isotopes”. The
radiobiological significance of ‘*‘I microdosimetry has been the subject of another
study by Reddy and Nagpa137. They have brought out the radiobiological differences
due to 131Z  and lzZ in rat thyroid using one month old rats ‘instead of adults. As these
normal young rats grow to three months age their thyroid weight increases by about
three times. This increase in thyroid weight is largely due to cell proliferation and
should be hampered to varying degrees for the same mean gland dose from 13’Z and
lSZ. The effect of radiation on the thyroid cell proliferation can therefore be studied
directly without the use of a goitrogenic challenge. Different doses of ‘=Z and I311
were administered.to different groups of one month old rats. They were then monitored
for their body growth and thyroidal radioiodine retention for a period of two months.
At the end, a tracer dose was administered to determine the 24-hr  thyroid uptake.
The animals were then sacrificed, their thyroids weighed, and the percentage uptake
determined. The thyroidal weights were converted into percentage cell survivals.
When compared between 100 &i of ‘*‘Z and 71 ,uCi of 131Z,  the body weight was
impaired more with ‘=Z, whereas the 24-hr uptake was significantly reduced with 131Z.
The 50 per cent cell survival dose with ‘=Zwas  about two times that with 131Z.
With a view to see whether the non-homogeneity of radiation dose distribution
at the microscopic level with ‘=Z has a different ultrastructural effect on the follicular
cell compared to 131Z  Puri, et al made an electron microscopic study of the time course
of radiation effects on rat thyroid using 50 &i of lzZ and 13’Z each3*. The mean dose
delivered to the thyroid gland with 50 ,uCi of lzZ was 7500 rad and that with 13*Z  was
22,000 rad. Though there is a marked inhomogeneity in dose distribution across the
follicular cell in the case of lzZ, the ultrastructural changes observed with both isotopes
were, in general, similar. The most affected part of the follicular cell was the apical
membrane which was followed by the alphacytomembranes. Although the
radiobiological and dosimetric basis of ‘=Z therapy of hyperthyroidism was quite
encouraging (leading one to expect that late onset of hypothyroidism, a frequent
concomitant of r31Z therapy, could be minimised), clinical trials using lzsZ  have not
been successfu139.
In spite of this failure, microdosimetry of lzZ and many other Auger electron
emitters has remained a subject of recent research in view of their success as suitable
labels that could target on to any part of a cell. The subject received further impetus
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and importance with labelled  monoclonal antibodies coming up as potential
immunoradiotherapeutic agents for tumour therapy. The status of the local dose
estimates and the microdosimetry of Auger electron emitters have recently been
reviewed4.  For a number of radionuclidesthe  mean energy deposited per decay in
microspheres having radii in the range of micrometers to nanometers has been
computed. Details of the variations in the intensities of the emitted radiations in’
individual radionuclide decay, energy depositions due. to each emission in the
microtargets of interest, as well as the energy transfer due to charge migrations along ’
the molecule in which the radionuclide has decayed, have been considered in order
to obtain the relevant dose and assess its potential-biological effect.
5. FUTURE TRENDS
Researchers concerned with radioactive substances have always striven to get
better and better estimates of the radiation absorbed dose; particularly so in the field
of medical applications of radiation and radionuclides. The real goal of the dosimetrist
has been to clarify the relationships between interaction of radiation with matter and
the biological effects. Important physical information inputs for such a goal are: (i)
detailed knowledge of the. source region, such as it size, geometry, composition
molecular nature, etc., (ii) the details of radioactive decay, such as type of radiations
emitted, their energies and yields, and (iii) details of the interactions of the above
radiations with the source materials, such as radiation interaction cross-sections,
transport equations, and techniques to compute the energy deposition,in  the source
region or any other region of interest, and probability distribution of interaction events
that result in energy deposition. While these are fairly straightforward, albeit complex
and tedious to obtain, the biological information-such as temporal kinetics of the
radionuclide in the source region, consequences of radioactive decay at the site of
decay and surroundings due to transmutational changes-has remained complex. With
the availability of radioactive labels to tag any part of a cell, the situation has become
more difficult.
It appears that in future, the following programmes will receive wider attention
and solutions have to emerge:
(a) More concerted efforts to collect biokinetic datg for all
radiopharmaceuticals, including those with ultra-short half-lives, for normal
human model, disease states, medication, lactation, age, sex, use of blocking
agents, etc.
(b) Embryo/fetus dosimetry which requires definition of a suitable model
of the embryo/fetus weight vs its gestational age arriving at an age-dependent
anthropometric model for embryo/fetus;. estimation of the transplacental
cross-over of the radionuclides administered to the mother. Information on
this latter aspect is next to impossible to get in view of ethical and medico-legal
considerations. However, appropriate animal models may give some answers.
(c) The confusion between conventional dosimetry, millidosimetry,
microdosimetry and nanodosimetry will have to be sorted out. Basically, all
these forms of dosimetry are the same and adhere to the MIRD schema of
Loevinger and Berman. Energy deposited. in a region due to a radioactive
source decaying in it is the parameter of interest. The linear dimensions of
the region of interest begin shrinking from mm to pm to nm depending upon
Dosimetry of Internal Emiiers 397
the identification of the biologically significant target, deposition of a certain
amount of energy in which causes the measured effect-for example, from
an organ to its tissues, to its cells, to its nucleus, and from nucleus to the
DNA. Such local or HILED  (highly localised energy density) dosimetry
(common terms alternately used for milli,  micro or nanodosimetry) estimates
have mostly ‘been non-stochastic or mean dose values. As per many studies .
involving Auger electron emitters used as labels to DNA or plasma membrane
or to any other part of the cell, the energy deposited in that target correlates
well with the biological effects (mostly cell survival or DNA strand breaks
observed). Will the future hold the same prospect?
(d) Stochastic nature of radioactive decay and the consequent stochastic
nature of energy deposition in targets of smaller and smaller dimensions are
being worked out.‘The  probability distributions of the specific energy imparted
to such targets have been computed for some electron emitters and some
alpha emitters. This methodology, called microdosimetry (entirely different
in concept from the microdosimetry mentioned earlier), also calculates the
number of targets that would not receive any energy deposition at all, in
addition to the probability distribution mentioned above. The radiobiological
significance of this microdosimetry is still not clear. Microdosimetry of external
radiation beams, (proposed nearly 25 years ago) is being appreciated now in
the protection range and niicrodosimetry counters adhering to ICRU norms
have been designed and are in use. Will it take that long a number of years
for microdosimetry of internal emitters to find relevance? It should be
mentioned that in the case. of Auger electron emitters, energy deposition
around the site of radioactive decay is highly intense and localised, and hence
really no probability distributions can be worked out; since the amount.of
radioactivity available in the source region is small, the process of radioactive
decay as well as the intensities of different radiations (including Auger,
Coster-Kronig electrons) emitted consequent upon decay will certainly exhibit
widely distributed probabilities.
(e) With the advent of monoclonal antibodies, particularly labelled  with
alpha emitters or Auger. electron emitters, prospects for
radioimmunotherapeutic drugs .seem to be increasing. The coming years
promise large strides in the microdosimetry of this new class of radiolabelled
antibodies.
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